Fapon Showcases High-Performance IVD Raw Materials at JACLaS EXPO 2026

News provided by

06 Oct, 2026, 08:00 CST

KOBE, Japan, Oct. 6, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider, will showcase its one-stop IVD solution at JACLaS EXPO 2026, held October 8–10 in Kobe, Japan. Visit Booth B32, Hall 1, 1st Floor.

Fapon will spotlight its latest breakthroughs in small molecule sandwich antibodies and mouse-free IgG blockers. The small molecule sandwich antibody panel covers Vitamin D (25-OH VD), Estradiol (E2), and Thyroxine (fT4/T4), delivering high sensitivity and strong clinical correlation against gold-standard mass spectrometry. On the CLIA platform, the assay achieves LoD of 1.0 ng/mL for 25-OH VD, 1.0 pg/mL for E2, and LoB as low as 0.000989 ng/dL for free T4, with 25-OH VD and E2 antibodies showing R² of 0.96 and 0.99 against LC-MS/MS respectively.

The mouse-free IgG blocker series addresses HAMA and RF interference with excellent lot-to-lot consistency and animal-origin-free formulation. The portfolio includes HIER-R-010, HIER-R-066, and HIER-R-061, with lot-to-lot variation controlled within 15% and cross-linked formulations for enhanced blocking performance.

In addition, Fapon will display its recombinant calibrator and control raw material series, covering TORCH, RF, CRP, HIV/HIV-P24, CKMB, HCV, TP, and HBV. Supported by scalable fermentation from 0.8L to 60L, it ensures reliable long-term supply. The booth will also feature AD blood-based biomarker raw materials and molecular diagnostic enzymes.

Since entering the international market in 2007, Fapon has built a global footprint spanning over 70 countries and 2,500+ partners worldwide. This marks Fapon's first appearance at JACLaS EXPO. Attendees are welcome to stop by to meet Fapon experts, discuss assay optimization and new pipeline planning needs, and explore tailored solution support for diagnostic projects.

About Fapon

Fapon, a globally leading life sciences organization, is redefining the R&D paradigm in diagnostics and therapeutics through a cutting-edge "AI-driven + a closed loop of dry and wet experiments" model. This approach significantly accelerates novel biomarker/target discovery and translation. We have established an integrated business structure that combines AI-powered innovative discovery, one-stop diagnostic solutions and novel therapies. Our products and services have covered the full spectrum of health management across the entire lifecycle, and accelerated the development of precision medicine.

SOURCE Fapon